For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
LDL cholesterol control: Would you like ezetimibe with your statin?
+Practice
In print
Heartbeat
LDL cholesterol control: Would you like ezetimibe with your statin?
Wednesday 30 August 2023, 12:25 AM

[ECG supplied]
Consultant cardiologist Chris Ellis discusses the secondary prevention of cardiovascular disease via lowering of low-density lipoprotein cholesterol
Key points, Atorvastatin 80mg (top dose) will reduce low-density lipoprotein cholesterol by about 55 per cent.
Rosuvastatin 40mg (top dose) will lower LDL chole, Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):111–88.